177944-16-0

Basic information

• Product Name: (R)-N-(but-3-en-1-yl)-N-(α-methylbenzyl)amine
• Synonyms: (R)-N-(but-3-en-1-yl)-N-(α-methylbenzyl)amine
• CAS NO: 177944-16-0
• Molecular Weight: 175.274
• Mol File: 177944-16-0.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: (R)-N-(but-3-en-1-yl)-N-(α-methylbenzyl)amine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-(but-3-en-1-yl)-N-(α-methylbenzyl)amine(177944-16-0)
• EPA Substance Registry System: (R)-N-(but-3-en-1-yl)-N-(α-methylbenzyl)amine(177944-16-0)

Safety Data

• Hazardous Substances Data: 177944-16-0(Hazardous Substances Data)

Usage

General Description

(R)-N-(but-3-en-1-yl)-N-(α-methylbenzyl)amine is a chemical compound with the molecular formula C15H21N. It is an amine derivative that contains a but-3-en-1-yl group and an α-methylbenzyl group. (R)-N-(but-3-en-1-yl)-N-(α-methylbenzyl)amine is used as a building block in organic synthesis and pharmaceutical research. It is also known for its potential therapeutic applications, including its use as a precursor in the synthesis of certain biologically active compounds. Its structure and properties make it a versatile and valuable chemical compound in the field of medicinal chemistry and drug discovery.

Upstream product

• 1258980-85-6 2-(but-3-enyl((R)-1-phenylethyl)amino)propanenitrile 
• 1258980-86-7 2-(but-3-enyl((R)-1-phenylethyl)amino)-2-cyclohexylacetonitrile 
• 1258980-87-8 methyl 2-(but-3-enyl-((R)-1-phenylethyl)amino)-2-cyanatoacetate 
• 1258980-79-8 (R)-2-(but-3-enyl(1-phenylethyl)amino)acetonitrile 
• 4111-54-0 lithium diisopropyl amide 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 40671-34-9 4-methanesulfonyloxy-1-butene 
• 778-29-0 but-3-enyl 4-methylbenzenesulfonate 
• 5162-44-7 1-bromo-4-butene 

Downstream Products

• 178035-48-8 (1R,5S)-2-((R)-1-phenylethyl)-6-oxa-2-azabicyclo[3.2.1]octan-7-one 
• 178035-47-7 (1S,5R)-2-[(1R)-1-phenylethyl]-6-oxa-2-azabicyclo[3.2.1]octan-7-one 
• 1202038-90-1 tert-butyl (3S,αR,E)-3-[N-(but-3′-en-1′-yl)-N-(α-methylbenzyl)amino]hex-4-enoate 
• 81838-65-5 tert-butyl hexa-3,5-dienoate 
• 1202039-35-7 (RS)-tert-butyl 3-butylhept-6-enoate 
• 1202038-98-9 tert-butyl (3R,αR)-3-[N-but-3'-enyl-N-(α-methylbenzyl)amino]hept-6-enoate 
• 1202038-99-0 methyl (3R,αR)-3-[N-but-3'-enyl-N-(α-methylbenzyl)amino]hept-6-enoate 
• 1258980-85-6 2-(but-3-enyl((R)-1-phenylethyl)amino)propanenitrile 
• 1258980-86-7 2-(but-3-enyl((R)-1-phenylethyl)amino)-2-cyclohexylacetonitrile 
• 1258980-79-8 (R)-2-(but-3-enyl(1-phenylethyl)amino)acetonitrile 
• 1273232-46-4 tert-butyl (3S,4S,5R,αR)-3-[N-but-3'-enyl-N-(α-methylbenzyl)amino]-4,5-O-isopropylidenehept-6-enoate 
• 1273232-24-8 tert-butyl (2R,3S,4S,5R,αR)-2-hydroxy-3-[N-but-3'-enyl-N-(α-methylbenzyl)amino]-4,5-O-isopropylidenehept-6-enoate 
• 1345893-78-8 tert-butyl but-3-enyl(R)-1-phenylethylcarbamate 
• 1345893-79-9 tert-butyl 5-oxo-5-phenylpentyl(R)-1-phenylethylcarbamate 

Relevant articles and documents

3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of formula (I') and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

A 5 + 1 Protic Acid Assisted Aza-Pummerer Approach for Synthesis of 4-Chloropiperidines from Homoallylic Amines

We report that HCl·DMPU induces the formation of (thiomethyl)methyl carbenium ion from DMSO under mild conditions. Homoallylic amines react with this electrophile to generate 4-chloropiperidines in good yields. The method applies to both aromatic and aliphatic amines. The use of HCl·DMPU as both non-nucleophilic base and chloride source constitutes an environmentally benign alternative for piperidine formation. The reaction has a broad substrate scope, and the conditions offer good chemical yields with high functional group tolerance and scalability.

(Indazol-4-YL) Hexahydropyrrolopyrrolones and Methods of Use

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein GAr, L1, Z1 and Z2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.